Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Olsztyn – page 19

302 clinical trials in Olsztyn, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Olsztyn at a glance
302
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

302 trials in Olsztyn

Open in trial search

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:Opthea Limited

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Acasunlimab and Pembrolizumab for Patients with Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Small cell lung cancer+1

Not recruiting

Study of Atezolizumab, Carboplatin, and Etoposide with or Without Tiragolumab for Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Non-small cell lung cancer

Not recruiting

Study of Cemiplimab and Chemotherapy Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Acne

Not recruiting

Study of N-Acetyl-GED-0507-34-LEVO 5% gel applied daily for 12 weeks in patients with acne vulgaris

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
  • Sponsor:PPM Services S.A.

Acne

Not recruiting

Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
  • Sponsor:PPM Services S.A.

Cardiac failure acute

Not recruiting

Study of dapagliflozin effects in patients hospitalized with acute heart failure

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin Propanediol Monohydrate
  • Sponsor:The Brigham And Women’s Hospital Inc.

Alopecia areata

Not recruiting

Study on Rezpegaldesleukin for Treating Severe Alopecia Areata in Adults

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Volrustomig with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Olsztyn

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on acute myeloid leukemia treatments and innovative therapies for various types of lung cancer. Studies include evaluation of new drug combinations and treatment approaches for colorectal cancer and lymphoma.

  • Advanced treatment combinations for leukemia
  • Targeted therapies for NSCLC
  • Novel approaches in lymphoma treatment

Research emphasizes personalized medicine approaches and improving patient outcomes in advanced stages of disease.

02 Dermatology Studies

Innovative research into plaque psoriasis and psoriatic arthritis treatments, including new biological therapies and novel drug combinations. Studies also examine treatments for rare conditions like pyoderma gangrenosum.

  • Biological therapy assessment
  • Chronic skin condition management
  • Combined treatment approaches

Focus on developing more effective treatments for moderate to severe skin conditions.

03 Cardiovascular Research

Studies examining new approaches to heart failure prevention and treatment, including investigations of novel drug combinations. Research focuses on reducing cardiovascular events and improving outcomes in high-risk patients.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Therapeutic combinations

Emphasis on preventive measures and innovative treatment strategies for cardiac conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.